Floatz logo

Fam-Trastuzumab Deruxtecan-Nxki

HER2 Low Breast Carcinoma

QuantumLeap Healthcare CollaborativePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the HER2 Low Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Elacestrant
Kristina A. Fanucci
Phase 3BB
Zanidatamab
QuantumLeap Healthcare Collaborative
Phase 2BB
Amiloride
Laura Huppert, MD, BA
Phase 2CCC
Shr-A1811
Henan Cancer Hospital
Phase 2CCC
Shr-A1811 For
Henan Cancer Hospital
Phase 2CCC
Patritumab Deruxtecan
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2CCC
Evorpacept
QuantumLeap Healthcare Collaborative
Phase 1CC

Same molecule, other indications

Fam-Trastuzumab Deruxtecan-Nxki is also rated in:

HER2 positive breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →